Arvinas Analyst Ratings
Barclays Maintains Arvinas(ARVN.US) With Buy Rating, Maintains Target Price $48
Truist Financial Maintains Arvinas(ARVN.US) With Buy Rating
Analysts Conflicted on These Healthcare Names: BioLife Solutions (BLFS), Arvinas Holding Company (ARVN) and Natera (NTRA)
Morgan Stanley Maintains Arvinas(ARVN.US) With Hold Rating, Cuts Target Price to $48
Stifel Maintains Arvinas(ARVN.US) With Buy Rating, Cuts Target Price to $63
Arvinas Holding Company (ARVN) Receives a Buy From Stifel Nicolaus
Analysts Have Conflicting Sentiments on These Healthcare Companies: Teladoc (TDOC), Arvinas Holding Company (ARVN) and Jazz Pharmaceuticals (JAZZ)
Truist Financial Keeps Their Buy Rating on Arvinas Holding Company (ARVN)
Truist Financial Maintains Arvinas(ARVN.US) With Buy Rating
Arvinas Price Target Maintained With a $87.00/Share by HC Wainwright & Co.
Buy Rating Affirmed for Arvinas Amidst Promising Clinical Trials and Strong Financial Outlook
Arvinas Price Target Maintained With a $57.00/Share by Wedbush
The Latest Analyst Ratings For Arvinas
A Quick Look at Today's Ratings for Arvinas(ARVN.US), With a Forecast Between $48 to $87
Arvinas Analyst Ratings
Barclays Sticks to Their Buy Rating for Arvinas Holding Company (ARVN)
Buy Rating Affirmed for Arvinas Holding Company Amid Promising Clinical Trial Developments
Arvinas Has Enough Funds to Cover Operating Expenses, Capex Into 2027 >ARVN
Piper Sandler Maintains Arvinas(ARVN.US) With Buy Rating, Maintains Target Price $67
No Data
No Data